There were 1,865 press releases posted in the last 24 hours and 358,819 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
Myovant Sciences Announces 88% One-Year Response Rate in Positive Phase 3 LIBERTY Extension Study of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image